文献速递淋巴瘤造血干细胞移植与细胞治疗

促红细胞生成素特异性刺激T淋巴细胞用于过继性免疫治疗

Specific stimulation of T lymphocytes with erythropoietin for adoptive immunotherapy.
PubMed 文献 · Blood · 2020-01-01

研究通过在人T淋巴细胞中异位表达野生型促红细胞生成素受体或截短型受体EpoRm,使T细胞对Epo敏感;EpoRm表达更高、促增殖与存活作用更强,与抗CD19 CAR共表达后在Epo存在下体外扩增及杀伤CD19+白血病细胞更优,免疫缺陷小鼠中生理水平鼠Epo即可优先扩增EpoRm-CAR T细胞并显著提高抗白血病活性。

要点

  • EpoRm使T细胞对Epo敏感,Epo连接诱导STAT5磷酸化,可被无毒浓度ruxolitinib阻断。
  • EpoRm与抗CD19-41BB-CD3ζ CAR共表达可保持两者功能,Epo存在下体外扩增与长期杀伤更优。
  • 生理水平小鼠Epo即可优先扩增EpoRm-CAR T细胞并显著增强抗白血病活性。

核心结论

  • 通过异位表达EpoRm使过继T细胞对Epo敏感,可在输注后用Epo或ruxolitinib调节其水平以增强抗肿瘤活性并减少毒性。

研究设计与样本

  • 在人T淋巴细胞中表达野生型Epo受体或截短型EpoRm,并以双顺反子载体与抗CD19-41BB-CD3ζ CAR共表达,开展体外与免疫缺陷小鼠实验。

主要发现

  • 两种受体均可在人T淋巴细胞表达,Epo连接诱导STAT5磷酸化且被ruxolitinib阻断。
  • EpoRm表达更高、刺激更强,包括更优的T细胞存活与增殖。
  • Epo存在下EpoRm-CAR T细胞体外扩增优于CAR T细胞,长期培养中杀伤CD19+白血病细胞更有效。
  • 免疫缺陷小鼠中生理水平鼠Epo足以优先扩增EpoRm-CAR T细胞,抗白血病活性显著更高。

临床怎么用

  • 为过继T细胞装备EpoRm有望以更少输注细胞获得更高效应-靶比,输注后可用Epo或ruxolitinib调整其水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In adoptive T-cell immunotherapy of cancer, expansion and persistence of effector cells is a key determinant of response. We tested whether T lymphocytes could be rendered sensitive to erythropoietin (Epo) through ectopic expression of its wild-type receptor or a truncated form (EpoRm), which augments Epo signaling in erythrocyte progenitors. Both receptors could be expressed in human T lymphocytes; Epo ligation induced STAT5 phosphorylation, which was abrogated by nontoxic concentrations of the JAK1/2 inhibitor ruxolitinib. EpoRm had higher expression and triggered more potent stimulation than its wild-type counterpart, including superior T-cell survival and proliferation. Using a bicistronic vector, we expressed EpoRm together with an anti-CD19-41BB-CD3ζ chimeric antigen receptor (CAR), while maintaining the functions of each receptor. In the presence of Epo, EpoRm-CAR T cells had greater ex vivo expansion than CAR T cells and killed CD19+ leukemic cells more effectively in long-term cultures. In immunodeficient mice, physiologic levels of murine Epo were sufficient to preferentially expand EpoRm-CAR T cells, yielding a significantly higher antileukemic activity. Thus, outfitting adoptive T cells with EpoRm should yield greater effector-to-target ratios with a smaller number of infused cells; Epo or ruxolitinib administration could be used to adjust their levels postinfusion, maximizing antitumor activity and minimizing toxicity.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Vinanica N, Yong A, Wong D, et al. Specific stimulation of T lymphocytes with erythropoietin for adoptive immunotherapy. Blood. 2020. PMID: 31697835. doi:10.1182/blood.2019001645

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。